Investors on Wednesday frowned on news that Aspen Pharmacare is to pay the UK’s National Health Service (NHS) £8m after admitting anticompetitive behaviour, knocking its share price to its lowest level in nine years.

While the scale of the payment is relatively small for a company of Aspen’s size, the news deepened negative sentiment about the company, which has been punished by investors over concerns about the scale of its debt...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.